Areva Med acquires Macrocyclics

10/20/2011 | MolecularImaging.net

Areva Med, a subsidiary of Areva that develops the radioisotope lead-212, has acquired Macrocyclics. Macrocyclics produces chemical agents used to bind antibodies or proteins to radioisotopes for some nuclear medicine cancer treatments. Areva is building the Maurice Tubiana Laboratory in France for the production of medical-grade lead-212.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX